📉 The Financial Deep Dive
Anthem Biosciences announced its Q3 FY26 unaudited consolidated and standalone financial results, revealing a challenging quarter. Consolidated revenue from operations declined by 15.0% YoY to ₹4,231.53 Mn from ₹4,978.06 Mn in the prior year's corresponding quarter. Profit After Tax (PAT) witnessed a steeper fall of 25.3% YoY, reaching ₹928.17 Mn. This significant contraction in profitability was substantially impacted by an exceptional item of ₹253.71 Mn, recognized for provisions related to the new Labour Codes notified by the Government of India.
On a nine-month basis for FY26, the company presented a contrasting picture of growth. Consolidated revenue from operations increased by 11.2% YoY to ₹15,133.89 Mn, up from ₹13,613.56 Mn in the previous year. Consolidated PAT for the nine months also saw a positive uptick, growing by 9.1% YoY to ₹4,020.34 Mn.
Standalone results mirrored these trends. For Q3 FY26, revenue from operations stood at ₹4,165.75 Mn, a 16.4% decrease YoY. Standalone PAT for the quarter was ₹1,121.25 Mn, down 12.4% YoY. However, for the nine months ended December 31, 2025, standalone revenue grew 10.7% YoY to ₹15,068.12 Mn, with PAT showing robust growth of 19.6% YoY to ₹4,588.98 Mn. A standalone exceptional item of ₹249.84 Mn was booked for the labor code provisions.
🚩 Risks & Outlook
The primary risk highlighted is the impact of new labour code provisions on profitability, as evidenced by the substantial exceptional item in Q3. Investors will need to monitor the ongoing implementation and potential future costs associated with these regulations. While the nine-month performance indicates underlying business strength, the Q3 dip warrants attention to gauge if it's a one-off event or a sustained trend. The company's recent IPO in July 2025 and the approved allotment of equity shares under the Employee Stock Option Plan (ESOP) 2024 also introduce factors like potential dilution and post-IPO performance scrutiny.
Segment-wise, the CRDMO segment experienced a quarterly decline but showed year-to-date growth, while the Speciality Ingredients segment reported moderate growth, suggesting varied performance across business verticals. The forward view will focus on Q4 performance to assess the company's ability to navigate regulatory impacts and maintain its growth trajectory.